Rare Emergence of Drug Resistance in HIV-1 Treatment-Na ïve Patients Receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for 144 Weeks

Combination antiretroviral therapy containing 3 HIV-1 antiviral drugs has been the cornerstone for the treatment of HIV-1 infection for over 2 decades, while the advent of once-daily single tablet regimens have simplified treatment and greatly improved the quality of life of people burdened by HIV-1 infection [1]. The single-tablet regimen studied here, comprising the 3 antiviral drugs elvitegravir (EVG or E), emtricitabine (FTC or F), and tenofovir alafenamide (TAF) as well as the pharmaco-enhancer cobicistat (C) (known as Genvoya ® or E/C/F/TAF), is one of the latest complete HIV-1 treatment to gain regulatory approval for the treatment of HIV-1 infection in treatment-naïve patients.

Source: Journal of Clinical Virology - April 2, 2018 Category: Virology Authors: Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D. Miller, Christian Callebaut Source Type: research